A449drugs in Poland. In the majority of processes RWE confirms conclusions based on EE. RWE is of high quality slightly less often than EE, however it is twice less frequently assessed for reliability. As pharma companies strive to develop high quality RWE it still does not receive the attention it deserves from public funding decision makers.
Real World Evidence is increasingly being demanded by national payers and HTA agencies to substantiate and validate outcomes from clinical trials. Yet, the access and quality of existing databases is often very limited, what creates hurdles to evaluate evidence in ‘normal’ healthcare setting. In Poland key stakeholders have not yet fully embraced RWE as an evidence source though they have growing need for more evidence to allocate scarce resources. The coming years are crucial for the shape and accessibility of RWE in Poland – however, the standpoint and the needs of the key stakeholders are not yet recognized. Therefore, an exploratory survey was undertaken to map current awareness and expectations of physicians related to practical outcomes data and to identify pharmaceutical industry’s role in RWE generation. Consideration of stakeholder needs seems to be the natural step in the beginning of preparation for real world evidence system in Poland. The analysis showed significant physicians interest in practical evidence and broad spectrum of possible actions that can be undertaken to improve formal use of RWE in Poland. The differences in priorities between specializations are a good indicator of the unmet needs in certain therapeutic areas. Broadening doctors’, payers’, insurers’ and service-providers’ knowledge on RWE significance, raising awareness of practical implementation and improving accessibility could be crucial for shaping the RWE landscape in Poland and, consequently, for improving patient treatment results.
A 3 4 7 -A 7 6 6 A449 drugs in Poland. In the majority of processes RWE confirms conclusions based on EE. RWE is of high quality slightly less often than EE, however it is twice less frequently assessed for reliability. As pharma companies strive to develop high quality RWE it still does not receive the attention it deserves from public funding decision makers.
A97 hematology(n= 62), dermatology(n= 14) and psychiatry(n= 72), others(n= 3) from outpatient and inpatient care. The survey consisted of qualitative and quantitative questions covering areas such as the most trusted sources of RWE in Poland, pharma role in RWE generation vs. government's contribution, most desired type of RWE. The questionnaires were collected Sept-Nov 2014 (the total number of responses received n= 251). Data were analyzed using simple descriptive statistics. Results: Physicians demonstrated high degree of interest in evidence on practical outcomes, particularly in data on safety and effectiveness of treatment (over 90% of responders); at the same time 1 out of 5 doctors claimed that data on effectiveness are hardly accessible in Poland. Interesting differences regarding desired real life data were observed across specialties: i.e. treatment pathways and prescribing patterns were frequently valued by diabetologists (87%), while quality of life was often quoted by hematologists (87%). For psychiatrists (69%) data on direct treatment costs are highly important whereas data on patient compliance was most often mentioned by oncologists (79%). ConClusions: The research showed high physicians' interest in practical evidence and the variety of RWE perception. The differences in priorities between specializations indicate unmet needs in therapeutic areas. Broadening doctor's and other stakeholders knowledge in RWE data significance and improving its accessibility could be crucial for gaining doctor's advocacy for shaping RWE landscape in Poland and, consequently, for improving patient's treatment results.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.